Reflecting on today's fantastic #iMED2022, I am thrilled to share an app I've been creating to create high-quality🤓, collaborative🗺️, & dynamic 📈diagnostic #MedEd schemas! Schematify App Here: diagnostic-schema.herokuapp.com Video: youtube.com/watch?v=u-gjhf… Check it out: 1/

We have <1 med onc, surg onc, rad onc, gyn onc, & palliative doc for every 100k Filipinos. We need more oncologists & we must ensure equity in the #Philippines 🇵🇭 ETHAN Edward Christopher "Chris" Dee, MD Fred Ting Johanna Patricia A. Cañal JCO Global Oncology ascopubs.org/doi/abs/10.120…

The various looks of #AML are too familiar to me & imprinted in my brain. But reminding myself on #RareDiseaseDay that #AML is a rare disease (<200K in 🇺🇸) A shout out to all those working tirelessly to improve therapy options 4 pts w/ #AML & other heme malignancies. #endcancer

Clonal hematopoiesis is an expansion of blood stem cell clones caused by mutations in a recurrent set of genes. Our paper on factors mediating expansion of these mutant clones is published today. nature.com/articles/s4158… Thread below...

Sushmitha Nanja Reddy will present our findings on "Clonal hematopoiesis and response to ICI in HL" at the MSHO 2023 annual meeting. Congrats on the merit award! Karmanos Hematology/Oncology Fellowship Karmanos Cancer Institute Vik Dhillon Jeff Aguilar Julie Boerner

2 oral presentations and 5 posters at ASH 2023 from us! More details after the embargo! Felicitations! Vik Dhillon Sushmitha Nanja Reddy @LBP0818 Jeff Aguilar Dakshin Padmanabhan Karmanos Cancer Institute

Epigenetic aging and age acceleration can be potential biomarkers for targeted therapy in AML. More interesting data being shared by Vik Dhillon Jeff Aguilar #ASH23

#ASHKudos to this morning’s presentations in Emerging Tools, Techniques and AI in Hematology. Exciting to learn more about machine learning and computational models under development #ASH23

Our #ASH23 poster on meta-analysis of myeloid sarcoma, #3811, in 900s section. One of the largest cohorts of myeloid sarcoma, pooled to gain insights on the disease! Cc: Dakshin Padmanabhan #ASHKudos to mentor and PI Suresh Balasubramanian ash.confex.com/ash/2023/webpr…

#ASH23 News Daily Monday AM edition is out. Our piece ‘It’s time to sp(l)ice things up’ covers fantastic work by Salima Benbarche Abdel-Wahab Lab, which was presented at #ASH23 Plenary Session. ASH. Read it here: ashpublications.org/ashnewsdaily/n… Natasha Szuber Juliana Perez Botero MD (she/her) 🌈

Does NPM1 MT convey similar impact when in De Novo vs T/sAML? 👇✅ your 🗓️ for this session that begins at 245PM today! #ASH23 Vik Dhillon Jeff Aguilar Sushmitha Nanja Reddy @LakshmiBPotluri

Some key findings for OS based on ELN favourable risk and secondary type mutations on NPM1 mt in De novo and t-AML #ASH23 ash.confex.com/ash/2023/webpr…

“If you're not using it, you're like those kids who are coming out of college in 1990 and still they’re not learning how to use word processors.”

What a wonderful story put together by Dr.Kubota! Congrats to Dr. Maciejewski’s Lab ⁦Cleveland Clinic⁩ Molecular and clinical analyses of PHF6 mutant myeloid neoplasia provide their pathogenesis and therapeutic targeting | ⁦Nature Communications⁩ nature.com/articles/s4146…

Check out our interesting case report of pancytopenia post mild COVID recovery, featured as the cover story of Hematology Reports Vol. 16, Issue 1 Suresh Balasubramanian Vik Dhillon

Excited to present our work on Telomere biology gene mutations in MDS and IPSS-M(R) work here! Vik Dhillon Jeff Aguilar Karmanos Cancer Institute

Excited to present our poster on mutational site-specificity and concordance/discordance characteristics in myeloid sarcoma here at #ASCO24 ! Big thanks to mentor Suresh Balasubramanian cc: Dakshin Padmanabhan Karmanos Cancer Institute IMG Oncologists #leusm

How do TP53 configurations evolve with treatment and impact prognosis? Dakshin Padmanabhan will present intriguing findings tonight. Don’t miss it! #ASH24 ASH Wayne State University Karmanos Cancer Institute Karmanos Hematology/Oncology Fellowship Vik Dhillon Jeff Aguilar

Excited to share our latest findings! Join us this evening at Poster 2768 as sandhya dhiman presents on menin interaction and nuclear export inhibition in NPM1-mutant AML.#ASH24 ASH

Congratulations Vik Dhillon Abdulmoiz! Differential prognostic impact of NPM1-MT AML underscores the need for age-adapted risk stratification models MDPI Jeff Aguilar Sushmitha Nanja Reddy Julie Boerner Carmelo Gurnari Waled Bahaj, MD tariqkewan Valeria Visconte